Refine by MP, party, committee, province, or result type.
Finance committee Sure. One of the most common ones that almost everybody would know about happens to be a natural health product. It's nicotine replacement therapy—nicotine patches and gums. It took years for the government to gather enough information about the safety, quality, and efficacy to m
May 30th, 2012Committee meeting
David Skinner
Finance committee Thank you, Mr. Chair and members of the committee, for allowing me the opportunity to speak today about Bill C-38, the Jobs, Growth and Long-term Prosperity Act, on behalf of the consumer health products industry. Consumer Health Products Canada is a national industry associatio
May 30th, 2012Committee meeting
David Skinner
Health committee Actually, probably one of the most pertinent things we deal with all the time is trying to find the balance between regulating on something and educating on something. There are two aspects to health and wellness and promotion. One is how to eliminate risks or how to reduce risks
February 7th, 2012Committee meeting
David Skinner
Health committee I have a PowerPoint.
February 7th, 2012Committee meeting
David Skinner
Health committee Thank you, Madam Chair and members of the committee, for allowing us the opportunity to be here today to participate in this study of health promotion and disease prevention. Consumer Health Products Canada is a century-old trade association, representing the makers of products
February 7th, 2012Committee meeting
David Skinner
International Trade committee I can maybe provide a very quick answer from our perspective. We're not advocating the patent extension period. What we're talking about is a separate issue; that is, data protection for new uses. I don't really have anything I can provide you on the costs that might accrue to p
November 15th, 2011Committee meeting
David Skinner
International Trade committee Yes. I have several examples of ones that eventually occurred but that took many years. Famotidine is an example of where you would have had to research a different use for an already established prescription product. Famotidine has long been used, and has a good safety recor
November 15th, 2011Committee meeting
David Skinner
International Trade committee Just to make a finer point, one of the things that often gets confusing, and for me as well, is that the patent extension period isn't really what we're talking about. I can speak to the principle of innovation around having a year to recoup your research costs for innovation in
November 15th, 2011Committee meeting
David Skinner
International Trade committee Article 74a is what's in the European Union's legislation about a data protection period. It's a straight reference that can be pulled from the EU legislation.
November 15th, 2011Committee meeting
David Skinner
November 15th, 2011Committee meeting
David Skinner
International Trade committee They would take the position that data protection—there is a section within the food and drug regulations called Division 8. It is the area where new uses for already new chemical entities can get some additional data protection, but it doesn't apply to anything that is more esta
November 15th, 2011Committee meeting
David Skinner
International Trade committee I'll make it a quick answer. What we're seeking is to have the data provisions that are in the switch legislation for the European Union included in the trade agreement so that we can parlay those into a Canadian benefit. The reason for this is that Health Canada has said we wi
November 15th, 2011Committee meeting
David Skinner
International Trade committee Sure. In the United Kingdom, when the data protection period came into play through the European Union, and even slightly before that in terms of the U.K. government's recognition that in order to have sustainable health care, people needed to be more involved in their own health
November 15th, 2011Committee meeting
David Skinner
International Trade committee It's mostly because of two things. One is that companies will invest in markets where they can recoup their investment. That's the crass commercial side of it. So there's nothing in it for the company to introduce it in Canada until such time as they have basically recouped the
November 15th, 2011Committee meeting
David Skinner
International Trade committee Yes. It's not a simple matter of just exporting it. You would have to register it for sale in Canada, so you would have to go through the same process. We were talking about red tape reduction. For example, there's a process that one goes through to be able to decide on simvasta
November 15th, 2011Committee meeting
David Skinner